Outcome of Combined Hepatocellular and Cholangiocarcinoma of the Liver

Overview

Journal J Oncol

Specialty Oncology

Date 2010 Sep 28

PMID 20871663

Citations 21

Authors

Jue Wang

Fenwei Wang

Anne Kessinger

Affiliations

Soon will be listed here.

Abstract

Background. The objective of this study was to examine the epidemiology, natural history, and prognostic factors of combined hepatocellular and cholangiocarcinoma (cHCC-CC) using population-based registry. Methods. The Surveillance, Epidemiology, and End Results Program database (1973-2004) was used to identify cases of cHCC-CC. Multivariable logistic regression was used to evaluate factors associated with cancer-directed surgery (CDS). The influence of CDS on cancer specific survival was evaluated using Kaplan-Meier curves and Cox proportional hazards modeling. Results. A total of 380 cases of cHCC-CC were identified, which account for approximately 0.87% of primary liver tumors. Of all patients, 69.8% of patients had regional or distant stage; 65.6% of patients had poorly or undifferentiated histology. Only 44.9% of patients with localized disease, received CDS. By logistic regression analysis, being widowed, advanced stage, and earlier diagnosis year were associated with lower rate of utilization of CDS. In multivariate analysis, tumor stage, receipt of CDS, and recent year of diagnosis were found to be significant predictors for cancer-specific survival. Conclusions. Patients with localized cHCC-CC who are selected for CDS were strongly associated with improved survival. However, many patients with localized tumors did not receive potentially curative cancer-directed surgery. Further study is warranted to address the barriers to the delivery of appropriate care to these patients.

Citing Articles

A Case of First-line Atezolizumab Plus Bevacizumab Use in Recurrence of Combined Hepatocellular Cholangiocarcinoma After Surgical Resection.

Moffat G, Duan K, Knox J J Clin Exp Hepatol. 2024; 14(5):101430.

PMID: 38766623 PMC: 11097066. DOI: 10.1016/j.jceh.2024.101430.

Nodal recurrence mapping and clinical target volumes after resection of intrahepatic cholangiocarcinoma or combined hepatocellular-cholangiocarcinoma.

Yang Z, Wang L, Zhai Y, Zhao J, Ye F, Wang S Clin Transl Radiat Oncol. 2024; 45:100749.

PMID: 38425471 PMC: 10904232. DOI: 10.1016/j.ctro.2024.100749.

Camrelizumab plus gemcitabine and oxaliplatin for the treatment of advanced intrahepatic cholangiocarcinoma: a bi-centric observational retrospective study.

Zhang Y, Wang K, Feng J, Yuan L, Liang C, Xiang Y Front Oncol. 2023; 13:1101038.

PMID: 37197414 PMC: 10183568. DOI: 10.3389/fonc.2023.1101038.

Differentiation between combined hepatocellular carcinoma and hepatocellular carcinoma: comparison of diagnostic performance between ultrasomics-based model and CEUS LI-RADS v2017.

Li C, Zheng X, Guo H, Cheng M, Huang Y, Xie X BMC Med Imaging. 2022; 22(1):36.

PMID: 35241004 PMC: 8896152. DOI: 10.1186/s12880-022-00765-x.

Update on the association of hepatitis B with intrahepatic cholangiocarcinoma: Is there new evidence?.

Fragkou N, Sideras L, Panas P, Emmanouilides C, Sinakos E World J Gastroenterol. 2021; 27(27):4252-4275.

PMID: 34366604 PMC: 8316913. DOI: 10.3748/wjg.v27.i27.4252.

References

Okada S . Local ablation therapy for hepatocellular carcinoma. Semin Liver Dis. 1999; 19(3):323-8. DOI: 10.1055/s-2007-1007121. View

Fan S, Lo C, Liu C, Lam C, Yuen W, Yeung C . Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths. Ann Surg. 1999; 229(3):322-30. PMC: 1191696. DOI: 10.1097/00000658-199903000-00004. View

Sonnenday C, Dimick J, Schulick R, Choti M . Racial and geographic disparities in the utilization of surgical therapy for hepatocellular carcinoma. J Gastrointest Surg. 2007; 11(12):1636-46. DOI: 10.1007/s11605-007-0315-8. View

Chantajitr S, Wilasrusmee C, Lertsitichai P, Phromsopha N . Combined hepatocellular and cholangiocarcinoma: clinical features and prognostic study in a Thai population. J Hepatobiliary Pancreat Surg. 2006; 13(6):537-42. DOI: 10.1007/s00534-006-1117-1. View

Virani S, Michaelson J, Hutter M, Lancaster R, Warshaw A, Henderson W . Morbidity and mortality after liver resection: results of the patient safety in surgery study. J Am Coll Surg. 2007; 204(6):1284-92. DOI: 10.1016/j.jamcollsurg.2007.02.067. View

Kim H, Park C, Han K, Choi J, Kim Y, Kim J . Primary liver carcinoma of intermediate (hepatocyte-cholangiocyte) phenotype. J Hepatol. 2004; 40(2):298-304. DOI: 10.1016/j.jhep.2003.10.023. View

Chan A, Lo C, Ng I, Fan S . Liver transplantation for combined hepatocellular cholangiocarcinoma. Asian J Surg. 2007; 30(2):143-6. DOI: 10.1016/S1015-9584(09)60149-4. View

Poon R, Fan S, Lo C, Liu C, Ming Lam C, Yuen W . Improving perioperative outcome expands the role of hepatectomy in management of benign and malignant hepatobiliary diseases: analysis of 1222 consecutive patients from a prospective database. Ann Surg. 2004; 240(4):698-708. PMC: 1356471. DOI: 10.1097/01.sla.0000141195.66155.0c. View

Koh K, Lee H, Choi M, Lee J, Paik S, Yoo B . Clinicopathologic features and prognosis of combined hepatocellular cholangiocarcinoma. Am J Surg. 2005; 189(1):120-5. DOI: 10.1016/j.amjsurg.2004.03.018. View

10.

Dick E, Taylor-Robinson S, Thomas H, Gedroyc W . Ablative therapy for liver tumours. Gut. 2002; 50(5):733-9. PMC: 1773197. DOI: 10.1136/gut.50.5.733. View

11.

Bruix J, Hessheimer A, Forner A, Boix L, Vilana R, Llovet J . New aspects of diagnosis and therapy of hepatocellular carcinoma. Oncogene. 2006; 25(27):3848-56. DOI: 10.1038/sj.onc.1209548. View

12.

Phongkitkarun S, Srisuwan T, Sornmayura P, Jatchavala J . Combined hepatocellular and cholangiocarcinoma: CT findings with emphasis on multiphasic helical CT. J Med Assoc Thai. 2007; 90(1):113-20. View

13.

Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F . Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996; 334(11):693-9. DOI: 10.1056/NEJM199603143341104. View

14.

Allen R, LISA J . Combined liver cell and bile duct carcinoma. Am J Pathol. 1949; 25(4):647-55. PMC: 1942823. View

15.

Kassahun W, Hauss J . Management of combined hepatocellular and cholangiocarcinoma. Int J Clin Pract. 2008; 62(8):1271-8. DOI: 10.1111/j.1742-1241.2007.01694.x. View

16.

Imai Y, Oda H, Arai M, Shimizu S, Nakatsuru Y, Inoue T . Mutational analysis of the p53 and K-ras genes and allelotype study of the Rb-1 gene for investigating the pathogenesis of combined hapatocellular-cholangiocellular carcinomas. Jpn J Cancer Res. 1996; 87(10):1056-62. PMC: 5921002. DOI: 10.1111/j.1349-7006.1996.tb03110.x. View

17.

Shiratori Y, Yoshida H, Omata M . Management of hepatocellular carcinoma: advances in diagnosis, treatment and prevention. Expert Rev Anticancer Ther. 2002; 1(2):277-90. DOI: 10.1586/14737140.1.2.277. View

18.

Goodman Z, Ishak K, Langloss J, Sesterhenn I, Rabin L . Combined hepatocellular-cholangiocarcinoma. A histologic and immunohistochemical study. Cancer. 1985; 55(1):124-35. DOI: 10.1002/1097-0142(19850101)55:1<124::aid-cncr2820550120>3.0.co;2-z. View

19.

Wakasa T, Wakasa K, Shutou T, Hai S, Kubo S, Hirohashi K . A histopathological study on combined hepatocellular and cholangiocarcinoma: cholangiocarcinoma component is originated from hepatocellular carcinoma. Hepatogastroenterology. 2007; 54(74):508-13. View

20.

Lee W, Lee K, Heo J, Kim S, Choi S, Kim Y . Comparison of combined hepatocellular and cholangiocarcinoma with hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Surg Today. 2006; 36(10):892-7. DOI: 10.1007/s00595-006-3276-8. View